for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Madrigal Pharmaceuticals Inc

MDGL.OQ

Latest Trade

87.13USD

Change

-0.00(-0.00%)

Volume

57,068

Today's Range

86.70

 - 

89.66

52 Week Range

82.39

 - 

218.93

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Madrigal Pharmaceuticals Reports 2019 Q2 Loss Per Share $1.28

Aug 7 (Reuters) - Madrigal Pharmaceuticals Inc <MDGL.O>::MADRIGAL PHARMACEUTICALS REPORTS 2019 SECOND QUARTER FINANCIAL RESULTS AND HIGHLIGHTS.MADRIGAL PHARMACEUTICALS INC - PHASE 3 MAESTRO-NASH PROGRAM CONTINUES TO PROGRESS.MADRIGAL PHARMACEUTICALS INC - JIM DALY ADDED TO BOARD OF DIRECTORS AND BECKY TAUB PROMOTED TO PRESIDENT OF RESEARCH AND DEVELOPMENT.MADRIGAL PHARMACEUTICALS INC- QTRLY LOSS PER SHARE $1.28.MADRIGAL PHARMACEUTICALS INC - QUARTER-END CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $466.4 MILLION, COMPARED TO $483.7 MILLION AT DECEMBER 31, 2018.

Madrigal Pharmaceuticals Inc - QTRLY Net Loss $0.98 Per Share

Madrigal Pharmaceuticals Inc <MDGL.O>::MADRIGAL PHARMACEUTICALS REPORTS 2019 FIRST QUARTER FINANCIAL RESULTS AND HIGHLIGHTS.MADRIGAL PHARMACEUTICALS INC - QTRLY CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $477.8 MILLION.MADRIGAL PHARMACEUTICALS INC - QTRLY NET LOSS $0.98 PER SHARE.MADRIGAL PHARMACEUTICALS - LOOK FORWARD TO ADVANCING OUR PLANNED PHASE 3 CLINICAL TRIAL IN PATIENTS WITH NAFLD/NASH AND DYSLIPIDEMIA IN LATTER HALF OF THIS YEAR.".

Madrigal Pharmaceuticals To Present Additional Analyses Of Data From Phase 2 NASH Study With MGL-3196

April 8 (Reuters) - Madrigal Pharmaceuticals Inc <MDGL.O>::MADRIGAL PHARMACEUTICALS TO PRESENT ADDITIONAL ANALYSES OF DATA FROM THE PHASE 2 NASH STUDY WITH MGL-3196 (RESMETIROM) AT THE INTERNATIONAL LIVER CONGRESS 2019.MADRIGAL PHARMACEUTICALS INC - DATA SUGGEST THAT REDUCTION OF HEPATIC FAT IS A CRITICAL COMPONENT OF NASH IMPROVEMENT AND RESOLUTION.MADRIGAL PHARMACEUTICALS INC - MRI-PDFF RESPONSE AT 12 WEEKS CORRELATED WITH REDUCTION IN BALLOONING AND INFLAMMATION COMPONENTS OF NAS.

Madrigal Pharmaceuticals Says In Phase 2 Study Resmetirom Was Statistically Significantly Superior To Placebo In Resolving Nash On Biopsy

March 28 (Reuters) - Madrigal Pharmaceuticals Inc <MDGL.O>::MADRIGAL PHARMACEUTICALS INITIATES PHASE 3, MULTINATIONAL, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF MGL-3196 (RESMETIROM) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS AND/OR HEPATIC DECOMPENSATION.MADRIGAL PHARMACEUTICALS - IN PHASE 2 STUDY RESMETIROM WAS STATISTICALLY SIGNIFICANTLY SUPERIOR TO PLACEBO IN RESOLVING NASH ON BIOPSY.MADRIGAL PHARMACEUTICALS INC - IN PHASE 2 STUDY RESMETIROM APPEARED SAFE AND WAS WELL-TOLERATED.

Madrigal Pharmaceuticals Reports Q4 Basic And Diluted Net Loss Per Common Share Of $0.75

Feb 27 (Reuters) - Madrigal Pharmaceuticals Inc <MDGL.O>::MADRIGAL PHARMACEUTICALS REPORTS 2018 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS AND HIGHLIGHTS.QTRLY BASIC AND DILUTED NET LOSS PER COMMON SHARE $0.75.MADRIGAL PHARMA- AS OF DECEMBER 31, HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $483.7 MILLION, COMPARED TO $191.5 MILLION AT DECEMBER 31, 2017..Q4 EARNINGS PER SHARE VIEW $-0.74 -- REFINITIV IBES DATA.

Madrigal Pharmaceuticals Qtrly Loss Per Share $0.56

Nov 6 (Reuters) - Madrigal Pharmaceuticals Inc <MDGL.O>::MADRIGAL PHARMACEUTICALS REPORTS 2018 THIRD QUARTER FINANCIAL RESULTS AND HIGHLIGHTS UPCOMING CLINICAL EVENTS.BELIEVE WE HAVE SIGNIFICANT FINANCIAL RESOURCES TO FUND OUR CURRENTLY PLANNED PHASE 3 PROGRAMS.EXPECT TO BEGIN A PHASE 3 STUDY IN NASH IN LATE 2018 OR EARLY 2019.EVALUATING TRIAL DESIGN AND OBJECTIVES OF A PHASE 3 STUDY IN DYSLIPIDEMIA WHICH COULD BEGIN IN 2019.AS OF SEPTEMBER 30, 2018, MADRIGAL HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $488.5 MILLION.QTRLY LOSS PER SHARE $0.56.Q3 EARNINGS PER SHARE VIEW $-0.53 -- THOMSON REUTERS I/B/E/S.

Madrigal Pharmaceuticals Reports Qtrly Loss Per Share $0.45

Aug 7 (Reuters) - Madrigal Pharmaceuticals Inc <MDGL.O>::MADRIGAL PHARMACEUTICALS REPORTS 2018 SECOND QUARTER FINANCIAL RESULTS AND REVIEWS KEY CLINICAL ACHIEVEMENTS.AS OF JUNE 30, 2018, MADRIGAL HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $490.3 MILLION.QTRLY LOSS PER SHARE $0.45.QTRLY LOSS PER SHARE $0.45.AS OF JUNE 30, 2018, CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $490.3 MILLION, VERSUS $191.5 MILLION AT DEC 31, 2017.Q2 EARNINGS PER SHARE VIEW $-0.63 -- THOMSON REUTERS I/B/E/S.MADRIGAL PHARMACEUTICALS - "WE ARE IN A STRONG POSITION TO EXPEDITE THE MGL-3196 DEVELOPMENT PROGRAM IN NASH AND DYSLIPIDEMIAS".

Madrigal Pharmaceuticals Prices Public Offering of Common Stock

June 6 (Reuters) - Madrigal Pharmaceuticals Inc <MDGL.O>::MADRIGAL PHARMACEUTICALS-PRICING OF UNDERWRITTEN REGISTERED PUBLIC OFFERING OF 1,347,232 SHARES OF COMMON STOCK AT $305.00 PER SHARE.

Madrigal Pharmaceuticals Announces Proposed Public Offering Of Common Stock

June 5 (Reuters) - Madrigal Pharmaceuticals Inc <MDGL.O>::MADRIGAL PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.MADRIGAL PHARMACEUTICALS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $200 MILLION OF ITS COMMON STOCK.MADRIGAL PHARMACEUTICALS INC - IN ADDITION, EXISTING STOCKHOLDERS ARE OFFERING UP TO 363,625 SHARES OF MADRIGAL'S COMMON STOCK IN OFFERING.

Madrigal'S Mgl-3196 Achieves Liver Biopsy Endpoints In Phase 2 Clinical Trial

May 31 (Reuters) - Madrigal Pharmaceuticals Inc <MDGL.O>::MADRIGAL'S MGL-3196 ACHIEVES LIVER BIOPSY ENDPOINTS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AT 36 WEEKS IN PHASE 2 CLINICAL TRIAL.MADRIGAL PHARMACEUTICALS INC - MGL-3196 WAS WELL-TOLERATED WITH MOSTLY MILD AND A FEW MODERATE AES.MADRIGAL PHARMACEUTICALS INC - IN PHASE 2 CLINICAL TRIAL, MGL-3196 DEMONSTRATED STATISTICAL SIGNIFICANCE IN PRIMARY ENDPOINT.MADRIGAL PHARMACEUTICALS INC - MGL-3196 HAD 7 SAES, NONE DRUG RELATED, NONE OCCURRING MORE THAN ONCE, 5 IN MGL-3196, 2 IN PLACEBO-TREATED PATIENTS.MADRIGAL PHARMACEUTICALS -PHASE 2 CLINICAL TRIAL OF MGL-3196 ALSO SHOWED STATISTICALLY SIGNIFICANT RESULTS IN KEY SECONDARY ENDPOINTS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up